Canadian Biotech Longeveron Secures Groundbreaking Cardiac Stem Cell Tech for Heart Disease Treatment
2025-07-21
The Manila Times
Toronto, ON – Longeveron, a Canadian biotechnology company focused on developing innovative therapies for cardiovascular disease, has announced a significant milestone: the licensing of a novel cardiac-selective induced pluripotent stem cell (iPSC) ...Read more
